🔗 Share this article Users Stopping Slimming Medications Put On Pounds at a Quadrupled Rate Compared to Dieters Weight management involves long-term strategies. Fresh analysis suggests that people who stop using new GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise programs. Published data in a prominent health publication demonstrates that while overweight people often shed substantial amounts of their body weight while undergoing treatment, the weight returns at an average rate of 0.8 kg per month after stopping. "Individuals buying such treatments should be cognizant of the risk of rapid rebound weight gain when the therapy concludes," warns researcher Dr. Susan Jebb. This pace of regain implies a reversion to starting mass in about 18 months. Comparing Treatments The research, which reviewed dozens of studies involving thousands of patients, contrasted the effects of the injectable medications with older methods. Scientists emphasize that people who shed pounds through diet and exercise typically experience a less rapid creep back—perhaps 0.1 kg a month—post-intervention. Explaining the Rapid Rebound Experts believe the mode of action of the drugs is key to understanding the accelerated rebound. These medications copy a natural hormone called GLP-1, which moderates hunger. "Artificially providing GLP-1 concentrations several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition researcher. "Discontinuation of this medication leads to hunger is no longer kept in check, making binge eating far more likely." A Chronic Disease? Health authorities suggest the injections for people with weight-linked health risks, alongside recommended diet and exercise modifications. Many experts argue that, given the likelihood of weight regain, the treatment might need to be life-long. This opinion is echoed by drug manufacturers, who state that the findings "highlight the chronic character of excess weight," comparing it to managing conditions like high blood pressure. User Experiences People who have come off the jabs explain a powerful return of hunger. "It was like something that goes on and you become starving," said an individual. This difficulty is compounded if users have not adopted lasting lifestyle or habit changes during treatment. Growing Adoption Recent estimates indicate that a significant number of adults in the UK have tried these injections in the past year, with demand continuing to grow. Adoption is higher among females than males. The 40s and 50s demographic shows the highest level of interest. Many obtain the medications through private prescriptions rather than public health services. In conclusion, researchers caution that while the jabs are powerful agents for weight loss, they are not a magic cure and lasting health benefits hinges on integrated lifestyle support.
Weight management involves long-term strategies. Fresh analysis suggests that people who stop using new GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who halt conventional diet and exercise programs. Published data in a prominent health publication demonstrates that while overweight people often shed substantial amounts of their body weight while undergoing treatment, the weight returns at an average rate of 0.8 kg per month after stopping. "Individuals buying such treatments should be cognizant of the risk of rapid rebound weight gain when the therapy concludes," warns researcher Dr. Susan Jebb. This pace of regain implies a reversion to starting mass in about 18 months. Comparing Treatments The research, which reviewed dozens of studies involving thousands of patients, contrasted the effects of the injectable medications with older methods. Scientists emphasize that people who shed pounds through diet and exercise typically experience a less rapid creep back—perhaps 0.1 kg a month—post-intervention. Explaining the Rapid Rebound Experts believe the mode of action of the drugs is key to understanding the accelerated rebound. These medications copy a natural hormone called GLP-1, which moderates hunger. "Artificially providing GLP-1 concentrations several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition researcher. "Discontinuation of this medication leads to hunger is no longer kept in check, making binge eating far more likely." A Chronic Disease? Health authorities suggest the injections for people with weight-linked health risks, alongside recommended diet and exercise modifications. Many experts argue that, given the likelihood of weight regain, the treatment might need to be life-long. This opinion is echoed by drug manufacturers, who state that the findings "highlight the chronic character of excess weight," comparing it to managing conditions like high blood pressure. User Experiences People who have come off the jabs explain a powerful return of hunger. "It was like something that goes on and you become starving," said an individual. This difficulty is compounded if users have not adopted lasting lifestyle or habit changes during treatment. Growing Adoption Recent estimates indicate that a significant number of adults in the UK have tried these injections in the past year, with demand continuing to grow. Adoption is higher among females than males. The 40s and 50s demographic shows the highest level of interest. Many obtain the medications through private prescriptions rather than public health services. In conclusion, researchers caution that while the jabs are powerful agents for weight loss, they are not a magic cure and lasting health benefits hinges on integrated lifestyle support.